Photo: George Frey (Getty Images) Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald Trump would sign an order lowering drug prices. A surprise trade agreement between the U.S. and China on Monday morning sent stocks soaring. The Dow Jones Industrial Average, the S&P 500, and the Nasdaq were all up 2.5% or more in the first 30 minutes of trading. But pharmaceutical stocks weren’t invited to the party, after Trump said Sunday night that he would sign an executive order lowering drug prices in the United States. Trump signed the order Monday morning. Shares of Eli Lilly (LLY) were down 2% Monday morning, even after a new study found the company’s weight loss drug, Zepbound, beat Novo Nordisk’s Wegovy in a head-to-head trial. Novo Nordisk (NVO) was down 1.9% Monday morning. Johnson & Johnson (JNJ) was down 0.4%, while Novartis (NVS) was down 0.5%. Pfizer (PFE) was a rare pharma bright spot, up 2.2%. “Prescription Drug and Pharmaceutical prices will be REDUCED, almost immediately, by 30% to 80%. They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA!” Trump posted to his Truth Social app on Sunday night. The president wrote that under a new “Most Favored Nations Policy,” the U.S. would pay the same price as the nation that pays the lowest price. He said he would sign the executive order on Monday. Trump followed that up with a post Monday morning claiming that drug prices would be reduced by 59%, though he didn’t specify how he arrived at that number. Americans often pay much higher prices for drugs than people in other nations. A committee found last year that the net cost of Ozempic, for example, was $600 per month in the U.S., compared to $92 in the U.K. and $59 in Germany. For the latest news, Facebook, Twitter and Instagram. View Comments
Eli Lilly stock sinks as pharma misses out on the market rally
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...